BR112020005271A2 - proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica - Google Patents
proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica Download PDFInfo
- Publication number
- BR112020005271A2 BR112020005271A2 BR112020005271-0A BR112020005271A BR112020005271A2 BR 112020005271 A2 BR112020005271 A2 BR 112020005271A2 BR 112020005271 A BR112020005271 A BR 112020005271A BR 112020005271 A2 BR112020005271 A2 BR 112020005271A2
- Authority
- BR
- Brazil
- Prior art keywords
- polypeptide
- protein
- seq
- amino acid
- tfr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01001—Carboxylesterase (3.1.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
- C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
- C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762566898P | 2017-10-02 | 2017-10-02 | |
| US62/566,898 | 2017-10-02 | ||
| US201762583276P | 2017-11-08 | 2017-11-08 | |
| US62/583,276 | 2017-11-08 | ||
| US201862626365P | 2018-02-05 | 2018-02-05 | |
| US62/626,365 | 2018-02-05 | ||
| US201862678183P | 2018-05-30 | 2018-05-30 | |
| US62/678,183 | 2018-05-30 | ||
| US201862721396P | 2018-08-22 | 2018-08-22 | |
| US62/721,396 | 2018-08-22 | ||
| PCT/US2018/053747 WO2019070577A1 (en) | 2017-10-02 | 2018-10-01 | FUSION PROTEINS COMPRISING SUBSTITUTE ENZYM THERAPY ENZYMES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020005271A2 true BR112020005271A2 (pt) | 2020-09-15 |
Family
ID=64267892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020005271-0A BR112020005271A2 (pt) | 2017-10-02 | 2018-10-01 | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
Country Status (20)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS63818B1 (sr) | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| BR112020005271A2 (pt) | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
| CA3109763A1 (en) * | 2018-08-16 | 2020-02-20 | Denali Therapeutics Inc. | Engineered bispecific proteins |
| EP3894864A2 (en) | 2018-12-10 | 2021-10-20 | Denali Therapeutics Inc. | Lysosomal storage disorder biomarkers and methods of use thereof |
| JP7543290B2 (ja) | 2019-02-20 | 2024-09-02 | デナリ セラピューティクス インコーポレイテッド | 抗trem2抗体及びその使用方法 |
| AU2020252554B2 (en) * | 2019-04-03 | 2026-05-28 | Denali Therapeutics Inc. | Formulations of protein molecules comprising iduronate 2-sulfatase |
| CN110111326B (zh) * | 2019-05-15 | 2021-01-15 | 西安科技大学 | 基于ert系统的重建图像质量评价方法 |
| BR112022012230A2 (pt) | 2019-12-23 | 2022-08-30 | Denali Therapeutics Inc | Variantes de progranulina |
| US11124567B2 (en) | 2020-01-13 | 2021-09-21 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| WO2021158986A1 (en) * | 2020-02-07 | 2021-08-12 | Denali Therapeutics Inc. | Methods for the treatment of hunter syndrome |
| CR20230178A (es) * | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
| KR20220073454A (ko) * | 2020-11-26 | 2022-06-03 | 한미약품 주식회사 | 신규한 뇌 표적 지속형 단백질 결합체 및 이의 제조방법 |
| MA71665A (fr) | 2021-02-11 | 2025-05-30 | Denali Therapeutics Inc. | Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation |
| US20250018015A1 (en) | 2021-07-23 | 2025-01-16 | Denali Therapeutics Inc. | Methods for the treatment of hunter syndrome |
| IL311003A (en) | 2021-08-25 | 2024-04-01 | Denali Therapeutics Inc | Anti-2HER antibodies and methods of using them |
| AR128003A1 (es) | 2021-12-17 | 2024-03-20 | Denali Therapeutics Inc | PROTEÍNAS DE FUSIÓN QUE COMPRENDEN ENZIMAS DE a-L-IDURONIDASA Y MÉTODOS PARA LAS MISMAS |
| WO2023198661A1 (en) * | 2022-04-12 | 2023-10-19 | F. Hoffmann-La Roche Ag | Fusion proteins targeted to the central nervous system |
| CN119213030A (zh) * | 2022-05-16 | 2024-12-27 | 戴纳立制药公司 | 转铁蛋白受体结合结构域和包含其的蛋白 |
| WO2023244540A1 (en) | 2022-06-13 | 2023-12-21 | Denali Therapeutics Inc. | A quantitative pharmacological model of enzyme replacement therapy |
| CN115032377B (zh) * | 2022-08-11 | 2022-11-01 | 裕菁科技(上海)有限公司 | 一种粘多糖贮积症生物标记物及应用 |
| WO2024211624A1 (en) * | 2023-04-04 | 2024-10-10 | University Of Cincinnati | Novel treatment strategies for pancreatic cancer using recombinant acid sphingomyelinase |
| EP4698671A2 (en) | 2023-04-21 | 2026-02-25 | Denali Therapeutics Inc. | Methods of increasing sialic acid levels in recombinant glycosylated proteins |
| TW202542190A (zh) | 2023-12-20 | 2025-11-01 | 美商戴納立製藥公司 | 包含酸性α—葡萄糖苷酶之融合蛋白及其方法 |
| WO2025166045A1 (en) * | 2024-01-31 | 2025-08-07 | Alector Llc | β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF |
| TW202617982A (zh) | 2024-06-24 | 2026-05-01 | 美商戴納立製藥公司 | 包含經修飾之葡萄糖腦苷脂酶多肽之融合蛋白及其方法 |
| CN121652292A (zh) * | 2025-12-31 | 2026-03-13 | 中山圣湘海济生物医药有限公司 | Fc-hGH融合蛋白、编码核酸、载体、工程细胞及其构建与制备方法和应用 |
Family Cites Families (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6015555A (en) * | 1995-05-19 | 2000-01-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| EP1436316B1 (en) | 2001-04-30 | 2008-01-23 | ZyStor Therapeutics , Inc. | Subcellular targeting of therapeutic proteins |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| WO2003057179A2 (en) | 2002-01-11 | 2003-07-17 | Biomarin Pharmaceutical, Inc. | Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes |
| CN102268094A (zh) * | 2002-08-30 | 2011-12-07 | 比奥雷克西斯药物公司 | 被修饰的转铁蛋白抗体的融合蛋白 |
| US7388079B2 (en) | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| US20050142141A1 (en) * | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
| CN110496230A (zh) | 2003-02-11 | 2019-11-26 | 夏尔人类遗传性治疗公司 | 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗 |
| US20040258666A1 (en) | 2003-05-01 | 2004-12-23 | Passini Marco A. | Gene therapy for neurometabolic disorders |
| AU2003286870A1 (en) | 2003-06-05 | 2005-01-04 | Salk Institute For Biological Studies | Targeting polypeptides to the central nervous system |
| US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| BRPI0406605B8 (pt) | 2003-11-13 | 2021-05-25 | Hanmi Holdings Co Ltd | conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| NZ576986A (en) | 2004-01-30 | 2010-12-24 | Shire Pharmaceuticals Ireland Ltd | Production and purification of recombinant arylsulfatase A |
| WO2006007560A2 (en) | 2004-07-01 | 2006-01-19 | University Of Pennsylvania | Targeted protein replacement for the treatment of lysosomal storage disorders |
| ATE423140T1 (de) | 2005-01-05 | 2009-03-15 | F Star Biotech Forsch & Entw | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
| JP5137814B2 (ja) | 2005-04-06 | 2013-02-06 | ジェンザイム・コーポレーション | 治療ターゲティングのための酸不安定リンカーを介するpegおよびポリシアルリソソーム酵素のコンジュゲート |
| AR059089A1 (es) | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
| CA2641070C (en) | 2006-02-06 | 2017-01-03 | Ramot At Tel-Aviv University Ltd. | Enzyme replacement therapy for treating lysosomal storage diseases |
| WO2008054544A2 (en) | 2006-05-22 | 2008-05-08 | Immune Disease Institute, Inc. | Method for delivery across the blood brain barrier |
| US7871624B2 (en) * | 2006-06-27 | 2011-01-18 | Saint Louis University | Chimeral polypeptide composition for cross-placenta delivery |
| WO2008105796A2 (en) | 2006-06-29 | 2008-09-04 | Albert Einstein College Of Medicine Of Yeshiva University | Compounds and methods for detecting ricin and uses thereof |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| WO2008089339A2 (en) | 2007-01-18 | 2008-07-24 | Genzyme Corporation | Oligosaccharide conjugates for cellular targeting |
| PL3219795T3 (pl) | 2008-01-18 | 2024-09-16 | Biomarin Pharmaceutical Inc. | Wytwarzanie aktywnych wysoce fosforylowanych ludzkich enzymów sulfatazy lizosomalnej i ich zastosowania |
| WO2009137721A2 (en) | 2008-05-07 | 2009-11-12 | Zystor Therapeutics, Inc. | Lysosomal targeting peptides and uses thereof |
| CA2773133A1 (en) | 2009-08-28 | 2011-03-03 | Edward H. Schuchman | Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency |
| KR102000383B1 (ko) | 2009-09-29 | 2019-07-15 | 유니버시테이트 젠트 | 만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해 |
| JP2013507131A (ja) | 2009-10-09 | 2013-03-04 | アーメイゲン・テクノロジーズ・インコーポレイテッド | Cnsにおけるイズロン酸2−スルファターゼ活性を増加させるための方法および組成物 |
| CA2803166C (en) | 2010-06-25 | 2023-03-07 | Shire Human Genetic Therapies, Inc. | Cns delivery of therapeutic agents |
| KR20130043165A (ko) | 2010-06-25 | 2013-04-29 | 샤이어 휴먼 지네틱 테라피즈 인크. | 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들 |
| EP2588490B1 (en) | 2010-07-02 | 2017-02-22 | Angiochem Inc. | Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof |
| JP6131190B2 (ja) | 2010-09-29 | 2017-05-17 | オキシレイン ユーケー リミテッド | リン酸化n−グリカンの脱マンノシル化 |
| CN103154243A (zh) | 2010-10-15 | 2013-06-12 | 日本化学研究株式会社 | 糖链的非还原末端为甘露糖残基的糖蛋白的制造方法 |
| JP5913122B2 (ja) | 2010-11-08 | 2016-04-27 | Jcrファーマ株式会社 | 新規発現ベクター |
| CN103443125B (zh) | 2010-11-30 | 2019-05-03 | 霍夫曼-拉罗奇有限公司 | 低亲和力血脑屏障受体抗体及其用途 |
| US9206401B2 (en) | 2010-12-22 | 2015-12-08 | Fondazione Telethon | Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses |
| WO2012101671A1 (en) | 2011-01-25 | 2012-08-02 | Jcr Pharmaceuticals Co., Ltd. | Method for production of human recombinant iduronate 2-sulfatase |
| WO2012136790A1 (en) * | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Compositions comprising fusion proteins or conjugates with an improved half -life |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| WO2012159164A1 (en) | 2011-05-23 | 2012-11-29 | Phylogica Limited | Method of determining, identifying or isolating cell-penetrating peptides |
| LT2714752T (lt) | 2011-05-27 | 2018-03-12 | Amicus Therapeutics, Inc. | Nukreipiančių peptidų kopuliavimo ant rekombinantinių lizosominių fermentų būdai, skirti lizosominio kaupimo ligų gydymo pagerinimui |
| AU2012272815B2 (en) | 2011-06-22 | 2017-09-07 | The General Hospital Corporation | Treatment of proteinopathies |
| US20160145589A1 (en) | 2011-06-24 | 2016-05-26 | Green Cross Corporation | Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof |
| KR101158673B1 (ko) | 2011-06-24 | 2012-07-03 | 주식회사 지씨바이오 | 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법 |
| CA2842492A1 (en) | 2011-08-05 | 2013-02-14 | Bioasis Technologies, Inc. | P97 fragments with transfer activity |
| WO2013055888A2 (en) | 2011-10-12 | 2013-04-18 | Synageva Biopharma Corp. | Recombinant human naglu protein and uses thereof |
| CN104145015A (zh) | 2011-12-01 | 2014-11-12 | 安吉奥开米公司 | 靶向的溶酶体酶化合物 |
| US20140335163A1 (en) | 2011-12-01 | 2014-11-13 | Angiochem Inc. | Targeted iduronate-2-sulfatase compounds |
| US8486399B2 (en) | 2011-12-02 | 2013-07-16 | Armagen Technologies, Inc. | Methods and compositions for increasing arylsulfatase A activity in the CNS |
| US9682129B2 (en) | 2011-12-23 | 2017-06-20 | Shire Human Genetic Therapies, Inc. | Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase |
| BR112014024358A8 (pt) | 2012-03-30 | 2018-01-23 | Shire Human Genetic Therapies | administração subcutânea de iduronato-2-sulfatase |
| JP5855239B2 (ja) | 2012-04-23 | 2016-02-09 | 株式会社Nrlファーマ | ラクトフェリン融合タンパク質及びその製造方法 |
| JP6279466B2 (ja) | 2012-04-27 | 2018-02-14 | Jcrファーマ株式会社 | 新規な発現ベクター |
| WO2013177062A2 (en) | 2012-05-21 | 2013-11-28 | Genentech, Inc. | Methods for improving safety of blood-brain barrier transport |
| US20130323221A1 (en) | 2012-05-30 | 2013-12-05 | Biostrategies LC | Plant lectins as carriers of associated drug substances into animal and human cells |
| SG11201407017WA (en) | 2012-06-04 | 2014-12-30 | Irm Llc | Site-specific labeling methods and molecules produced thereby |
| WO2013185235A1 (en) | 2012-06-15 | 2013-12-19 | Angiochem Inc. | Targeted iduronidase compounds |
| US20140004097A1 (en) | 2012-06-29 | 2014-01-02 | Shire Human Genetic Therapies, Inc. | Method of producing recombinant iduronate-2-sulfatase |
| US9150841B2 (en) | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
| KR101380740B1 (ko) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
| WO2014022515A1 (en) | 2012-07-31 | 2014-02-06 | Bioasis Technologies, Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
| US10138474B2 (en) | 2012-08-17 | 2018-11-27 | Research Foundation Of The City University Of New York | Scavenger receptor uptake for fabry disease enzyme replacement therapy |
| MX367126B (es) | 2012-08-29 | 2019-08-06 | Hoffmann La Roche | Transporte para atravesar la barrera hematoencefálica. |
| WO2014082080A2 (en) | 2012-11-26 | 2014-05-30 | Callidus Biopharma, Inc. | Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases |
| ES2679374T3 (es) | 2012-11-27 | 2018-08-24 | Biomarin Pharmaceutical Inc. | Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas |
| CN104955946A (zh) | 2012-11-30 | 2015-09-30 | 安吉奥开米公司 | 靶向的艾杜糖醛酸-2-硫酸酯酶化合物 |
| CN105027138B (zh) | 2012-12-27 | 2018-01-26 | 施耐德电气It公司 | 可视化气流的系统和方法 |
| NZ711373A (en) | 2013-03-13 | 2020-07-31 | Bioasis Technologies Inc | Fragments of p97 and uses thereof |
| WO2014152940A1 (en) | 2013-03-14 | 2014-09-25 | Shire Human Genetic Therapies, Inc. | Mrna therapeutic compositions and use to treat diseases and disorders |
| SG11201509566RA (en) | 2013-05-20 | 2015-12-30 | Genentech Inc | Anti-transferrin receptor antibodies and methods of use |
| WO2014194427A1 (en) | 2013-06-06 | 2014-12-11 | Angiochem Inc. | Targeted iduronate-2-sulfatase fusion proteins |
| MX370570B (es) | 2013-06-07 | 2019-12-17 | Genzyme Corp | Marcador para trastornos de la esfingomielinasa acida y sus usos. |
| WO2015009052A1 (ko) * | 2013-07-16 | 2015-01-22 | 일동제약 주식회사 | 하이브리드 면역글로불린 fc와 효소의 융합단백질 |
| US10906981B2 (en) | 2013-07-19 | 2021-02-02 | The Regents Of The University Of California | Compositions and methods related to structures that cross the blood brain barrier |
| US20150023956A1 (en) | 2013-07-22 | 2015-01-22 | Armagen Technologies, Inc. | Methods and compositions for increasing enzyme activity in the cns |
| US20150093399A1 (en) | 2013-08-28 | 2015-04-02 | Bioasis Technologies, Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
| EP3041865A2 (en) | 2013-09-03 | 2016-07-13 | NovImmune S.A. | Readily isolated bispecific binding molecules with native format having mutated constant regions |
| JP6309427B2 (ja) | 2013-10-09 | 2018-04-11 | Jcrファーマ株式会社 | イズロン酸−2−スルファターゼの活性測定法 |
| JP6616189B2 (ja) | 2013-12-25 | 2019-12-04 | Jcrファーマ株式会社 | 血液脳関門を通過する新規抗トランスフェリン受容体抗体 |
| WO2015101586A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
| PL3092251T3 (pl) | 2014-01-06 | 2021-08-02 | F. Hoffmann-La Roche Ag | Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg |
| AU2015219339B2 (en) | 2014-02-19 | 2020-03-05 | Bioasis Technologies Inc. | P97-IDS fusion proteins |
| SMT201800511T1 (it) | 2014-04-01 | 2018-11-09 | Swedish Orphan Biovitrum Ab Publ | Sulfamidasi modificata e sua produzione |
| CA2943890A1 (en) | 2014-05-01 | 2015-11-05 | Bioasis Technologies, Inc. | P97-polynucleotide conjugates |
| EP3166626B1 (en) | 2014-07-11 | 2021-04-28 | Biostrategies LC | Materials and methods for treating disorders associated with sulfatase enzymes |
| US10068619B1 (en) | 2014-07-25 | 2018-09-04 | Western Digital Technologies, Inc. | Hand held storage device |
| WO2016025519A1 (en) | 2014-08-11 | 2016-02-18 | Shire Human Genetic Therapies, Inc. | Mannose-6-phosphate bearing peptides fused to lysosomal enzymes |
| PT3215528T (pt) | 2014-11-06 | 2019-10-11 | Hoffmann La Roche | Variantes da região fc com ligação modificada ao fcrn e métodos de utilização |
| JP2017534640A (ja) | 2014-11-10 | 2017-11-24 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | アルファ−l−イズロニダーゼ、イズロン酸−2−スルファターゼおよびアルファガラクトシダーゼaの治療用組成物ならびにそれらの使用方法 |
| MA40954A (fr) * | 2014-11-14 | 2017-09-19 | Shire Human Genetic Therapies | Détermination de niveaux de glycosaminoglycane par spectrométrie de masse |
| CA2967830A1 (en) | 2014-11-14 | 2016-05-19 | Ossianix, Inc. | Tfr selective binding compounds and related methods |
| EP3221361B1 (en) | 2014-11-19 | 2021-04-21 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
| JP6779876B2 (ja) * | 2014-11-19 | 2020-11-04 | ジェネンテック, インコーポレイテッド | 抗トランスフェリン受容体抗体及びその使用方法 |
| MA41198A (fr) | 2014-12-18 | 2017-10-24 | Shire Human Genetic Therapies | Essais d'activité enzymatique pour i2s |
| US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| EP3253884B1 (en) | 2015-02-05 | 2020-03-18 | R.P. Scherer Technologies, LLC | Activated formylglycine-generating enzymes and methods of producing and using the same |
| WO2016191869A1 (en) | 2015-06-01 | 2016-12-08 | The Hospital For Sick Children | Delivery of structurally diverse polypeptide cargo into mammalian cells by a bacterial toxin |
| CA2990785C (en) | 2015-06-24 | 2024-11-12 | Jcr Pharmaceuticals Co., Ltd. | ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER |
| ES2849248T3 (es) | 2015-06-24 | 2021-08-17 | Beumer Group As | Clasificador de línea |
| AU2016282334B2 (en) * | 2015-06-24 | 2022-07-21 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
| WO2017003270A1 (ko) | 2015-07-02 | 2017-01-05 | 주식회사 녹십자 | 헌터증후군 치료제 및 치료방법 |
| KR20170004814A (ko) | 2015-07-02 | 2017-01-11 | 주식회사 녹십자 | 헌터증후군 치료제 |
| WO2017055586A1 (en) | 2015-10-01 | 2017-04-06 | Swedish Orphan Biovitrum Ab (Publ) | Modified iduronate 2-sulfatase and production thereof |
| JP2018535654A (ja) | 2015-10-01 | 2018-12-06 | スウェディッシュ オーファン バイオビトラム アクティエボラーグ (ペーウーベーエル) | 修飾リソソームタンパク質とその製造 |
| WO2017062666A2 (en) | 2015-10-06 | 2017-04-13 | Patricia Dickson | Enzyme replacement therapy for mucopolysaccharidosis iiid |
| US20180221459A1 (en) | 2015-10-06 | 2018-08-09 | LA BioMedical Research Institute at Harbor-UCLA Medical Center | Enzyme replacement therapy for mucopolysaccharidosis iiid |
| MY207684A (en) | 2015-12-08 | 2025-03-12 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
| GB201522243D0 (en) | 2015-12-16 | 2016-01-27 | Ucl Business Plc | Treatment |
| HK1258054A1 (zh) | 2015-12-30 | 2019-11-01 | 株式会社绿十字 | 用於治疗亨特综合征的方法和组合物 |
| AR107483A1 (es) | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
| EP3419651B1 (en) | 2016-02-24 | 2023-10-25 | BioMarin Pharmaceutical Inc. | Improved naglu fusion protein formulation |
| WO2017151791A1 (en) | 2016-03-01 | 2017-09-08 | Biostrategies LC | Materials and methods for mitigating immune-sensitization |
| US11253612B2 (en) | 2016-04-15 | 2022-02-22 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type II |
| US10169252B2 (en) | 2016-07-15 | 2019-01-01 | International Business Machines Corporation | Configuring functional capabilities of a computer system |
| CA3033082A1 (en) | 2016-08-06 | 2018-02-15 | Ossianix, Inc. | In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use |
| CN109641971B (zh) | 2016-08-25 | 2023-04-04 | Jcr制药股份有限公司 | 抗体融合蛋白的制造方法 |
| EP3556399A1 (en) | 2016-12-19 | 2019-10-23 | Hanmi Pharm. Co., Ltd. | Brain targeting long-acting protein conjugate |
| TWI833178B (zh) * | 2016-12-26 | 2024-02-21 | 日商Jcr製藥股份有限公司 | 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體 |
| MX2019007824A (es) | 2016-12-28 | 2019-09-09 | Japan Chem Res | Preparacion liofilizada. |
| GB201701968D0 (en) | 2017-02-07 | 2017-03-22 | Univ Manchester | Gene therapy |
| RS63818B1 (sr) | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| CA3053379A1 (en) * | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| EP4628586A3 (en) | 2017-02-17 | 2026-01-14 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
| CA3053381A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Engineered polypeptides |
| JP7106289B2 (ja) | 2017-02-21 | 2022-07-26 | Jcrファーマ株式会社 | グリコサミノグリカンの分析法 |
| GB201702863D0 (en) | 2017-02-22 | 2017-04-05 | Evox Therapeutics Ltd | Improved loading of EVs with therapeutic proteins |
| WO2019009884A1 (en) | 2017-07-03 | 2019-01-10 | Mark Anthony Allen | VISUAL DRIVING AID FOR VEHICLE VISOR |
| US20200157172A1 (en) | 2017-07-07 | 2020-05-21 | HANMl PHARM. CO., LTD. | Novel therapeutic enzyme fusion protein and use thereof |
| KR20190013615A (ko) | 2017-07-28 | 2019-02-11 | 한미약품 주식회사 | 이두로네이트 2-설파타제 결합체 |
| WO2019032955A1 (en) | 2017-08-10 | 2019-02-14 | Denali Therapeutics Inc. | MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES |
| WO2019049967A1 (ja) | 2017-09-07 | 2019-03-14 | Jcrファーマ株式会社 | 水性医薬組成物 |
| BR112020005271A2 (pt) | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
| WO2019094608A1 (en) | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
| BR112020013921A2 (pt) | 2018-01-10 | 2020-12-01 | Denali Therapeutics Inc. | polipeptídeos de ligação ao receptor de transferrina e usos destes |
| WO2019246071A1 (en) | 2018-06-18 | 2019-12-26 | Denali Therapeutics Inc. | Fusion proteins comprising progranulin |
| CA3109763A1 (en) | 2018-08-16 | 2020-02-20 | Denali Therapeutics Inc. | Engineered bispecific proteins |
| EP3840781A1 (en) | 2018-08-22 | 2021-06-30 | Denali Therapeutics Inc. | Anti-her2 polypeptides and methods of use thereof |
| KR20200094577A (ko) | 2019-01-30 | 2020-08-07 | 주식회사 모비스 | 인공신경망 시뮬레이터와 강화학습 제어기를 사용한 실시간 가속기 제어 시스템 |
| AU2020252554B2 (en) | 2019-04-03 | 2026-05-28 | Denali Therapeutics Inc. | Formulations of protein molecules comprising iduronate 2-sulfatase |
| BR112022012230A2 (pt) | 2019-12-23 | 2022-08-30 | Denali Therapeutics Inc | Variantes de progranulina |
| WO2021146256A1 (en) | 2020-01-13 | 2021-07-22 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| US11124567B2 (en) | 2020-01-13 | 2021-09-21 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| WO2021158986A1 (en) | 2020-02-07 | 2021-08-12 | Denali Therapeutics Inc. | Methods for the treatment of hunter syndrome |
| CR20230178A (es) | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
-
2018
- 2018-10-01 BR BR112020005271-0A patent/BR112020005271A2/pt active Search and Examination
- 2018-10-01 CA CA3076369A patent/CA3076369A1/en active Pending
- 2018-10-01 IL IL273439A patent/IL273439B2/en unknown
- 2018-10-01 CN CN202511537510.7A patent/CN121780481A/zh active Pending
- 2018-10-01 JP JP2020516389A patent/JP7854267B2/ja active Active
- 2018-10-01 WO PCT/US2018/053747 patent/WO2019070577A1/en not_active Ceased
- 2018-10-01 SG SG11202002730XA patent/SG11202002730XA/en unknown
- 2018-10-01 CN CN201880068837.6A patent/CN111278859A/zh active Pending
- 2018-10-01 MA MA050746A patent/MA50746A/fr unknown
- 2018-10-01 US US16/649,943 patent/US20200277584A1/en not_active Abandoned
- 2018-10-01 MY MYPI2020001598A patent/MY209029A/en unknown
- 2018-10-01 PE PE2020000415A patent/PE20210347A1/es unknown
- 2018-10-01 KR KR1020207012168A patent/KR102997172B1/ko active Active
- 2018-10-01 EP EP18800356.0A patent/EP3692070A1/en active Pending
- 2018-10-01 EP EP21163125.4A patent/EP3904389A1/en active Pending
- 2018-10-01 CR CR20200129A patent/CR20200129A/es unknown
- 2018-10-01 AU AU2018345303A patent/AU2018345303B2/en active Active
- 2018-10-01 MX MX2020002918A patent/MX2020002918A/es unknown
-
2019
- 2019-03-15 US US16/355,339 patent/US10870837B2/en active Active
-
2020
- 2020-03-16 CO CONC2020/0003128A patent/CO2020003128A2/es unknown
- 2020-03-17 MX MX2024006720A patent/MX2024006720A/es unknown
- 2020-03-17 MX MX2023009913A patent/MX2023009913A/es unknown
- 2020-03-27 CL CL2020000810A patent/CL2020000810A1/es unknown
- 2020-03-30 SA SA520411662A patent/SA520411662B1/ar unknown
- 2020-04-29 PH PH12020550510A patent/PH12020550510A1/en unknown
- 2020-11-23 US US17/102,138 patent/US11866742B2/en active Active
-
2023
- 2023-10-02 JP JP2023171561A patent/JP2023179600A/ja active Pending
-
2025
- 2025-12-16 AU AU2025283436A patent/AU2025283436A1/en active Pending
-
2026
- 2026-02-06 JP JP2026018468A patent/JP2026077678A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11866742B2 (en) | Fusion proteins comprising enzyme replacement therapy enzymes | |
| US20230406898A1 (en) | Fusion proteins comprising progranulin | |
| JP2025120209A (ja) | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 | |
| US11884944B2 (en) | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof | |
| JP2016513114A (ja) | フォーズス・コリ病の処置のための方法および組成物 | |
| WO2013177428A1 (en) | Methods for increasing muscle contractility | |
| US12378540B1 (en) | Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof | |
| HK40063309A (en) | Fusion proteins comprising enzyme replacement therapy enzymes | |
| EA052434B1 (ru) | Слитые белки, содержащие ферменты для заместительной ферментной терапии | |
| HK40031685A (en) | Fusion proteins comprising enzyme replacement therapy enzymes | |
| HK40103089A (en) | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof | |
| WO2026006173A1 (en) | Fusion proteins comprising modified glucocerebrosidase polypeptides and methods thereof | |
| CN118591553A (zh) | 多肽工程化、文库和工程化cd98重链以及转铁蛋白受体结合多肽 | |
| EA051395B1 (ru) | Слитые белки, содержащие ферменты сульфоглюкозамин-гидролазы, и связанные с ними способы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] |